Phase 2 N=39 Transgender Estradiol Affirming Therapy
Transgenderism
Primary: Total Testosterone Level in Transgender Female Patients — 498.6; 481.3; 505.3; 62.7 pg/mL — p=0.005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Mental Health Support for Transgender and Gender-expansive Individuals
Transgender · Depression · Anxiety
Primary: Depression: Score on the Overall Depression Severity & Impairment Scale (ODSIS) — 9.68; 4.82 score on a scale
N/A N=986 Understanding Perceived Access and Receipt of Gender-affirming Treatments Among Transgender Veterans
Gender Dysphoria
Primary: Receipt of Gender Affirming Treatment — 769; 687; 292; 468 Participants
Phase 3 N=304 Pre-Exposure Prophylaxis for Transgender Women in the US and South America
HIV Prevention
Primary: PrEP Uptake — 16.2; 11.4 days
N/A N=49 TRANSLATE: Transgender and Gender Nonconforming Individuals' Access to Healthcare
Gender Identity
Primary: Change in Knowledge of TGNC Individuals of Total Number of Locations to Receive Medical Care in Cleveland Known — 3.79 locations
N/A N=321 The Experiences of Erotic and Sexual Risk of Transgender Men: Exploratory Research Design
Transgender Persons · Sexual Health
Primary: Experience of Erotic and Sexual Risk of Transgender Men(Demographic Data, Transgender Affirmation Questionnaire) — 269; 52; 166; 37 Participants
Early Phase 1 N=11 Transgender Estradiol
Transgender Persons
Primary: Maximum Serum Concentration of Estradiol — 144; 35 pg/mL
Phase 4 N=35 Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone
Gender Dysphoria, Adolescent
Primary: Number of Participants Satisfied With Self-Administered DMPA at Initiation — 17 Participants
Phase 4 N=48 Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy
HIV Prevention · Transgender Health
Primary: Tenofovir Diphosphate Concentration in Dried Blood Spots (DBS) — 973.5; 1078 fmol/punch
N/A N=254 TechStep: Technology-based Stepped Care to Stem Transgender Adolescent Risk Transmission
HIV
Primary: Condomless Intercourse Events — 3.14; 3.17; 3.68 Expected events — p=0.141
N/A N=37 Pelvic Floor Physical Therapy vs Standard Care in Transgender Women Undergoing Vaginoplasty for Gender Affirmation
Pelvic Floor Disorders
Primary: Patient Reported Ease of Dilation — 6.6; 7.4; 8.0 units on a scale
Phase 1 N=13 Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW
HIV · Prophylaxis · Transgender
Primary: Change in Maximum Tenofovir Plasma (Cmax) Concentration — 286; 276; 274; 277 ng/mL
Phase 1 N=8 Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
Transgender Health · Gender Dysphoria · Transgender Women
Primary: Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) — 17798.14; 18413.21 hr*ng/mL
N/A N=121 Promoting Viral Suppression Among Transgender Women Living With HIV in Santo Domingo
HIV
Primary: Number of Participants With Viral Suppression (HIV), 6 Months — 31; 33 Participants — p=0.489
N/A N=60 Empowerment Self-Defense Training for the Prevention of Victimization of Transgender Women
Violence, Sexual
Primary: Average Rating on Sexual Assertiveness at Baseline — 2.77 score on a scale